About US
Contact us
>>Back
Gilead Joins Medicines Patent Pool
- Publisher：
- Publication：2011/7/13
Gilead Sciences has signed up to the Medicines Patent Pool to improve access to HIV treatments in developing countries, becoming the first pharmaceutical firm to do so.
Founded in 2010, the Medicines Patent Pool enables drug manufacturers to produce cheaper, generic versions of drugs currently under patents for use in developing or poorer countries.
Gilead will now produce generic version of Viread and Emtriva, both used in the treatment of AIDs and Hepatitis, as well as two pipeline treatments, cobicistat and elvitegravir.
Licences distributed will allow the supply of both Viread and Emtriva in 111 countries, cobicistat in 102 countries and elvitegravir in 99 countries, with patent holders receiving small-scale royalties for their licensed technologies.